← Back to Clinical Trials
Recruiting NCT06876883

NCT06876883 MItral Regurgitation Risk Assessment and CLinical modElling

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06876883
Status Recruiting
Phase
Sponsor Sun Yat-sen University
Condition Mitral Insufficiency
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2016-06-15
Primary Completion 2030-06-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2016-06-15 with a primary completion date of 2030-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization. * Aged over 18 yrs. Exclusion Criteria: * Patients unable to provide written consent.

Contact & Investigator

Central Contact

Xiaodong Zhuang, MD

✉ zhuangxd3@mail.sysu.edu.cn

📞 +8613760755035

Frequently Asked Questions

Who can join the NCT06876883 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mitral Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06876883 currently recruiting?

Yes, NCT06876883 is actively recruiting participants. Contact the research team at zhuangxd3@mail.sysu.edu.cn for enrollment information.

Where is the NCT06876883 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06876883 clinical trial?

NCT06876883 is sponsored by Sun Yat-sen University. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology